Head-to-head · WeighScore
RestorLife Med vs YourHealthRx
The verdict
YourHealthRx takes it — 69.6/100 to 65.3/100.
YourHealthRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. YourHealthRx is a scientist-founded peptide and GLP-1 telehealth platform available in all 50 states and DC via a multi-state (IMLC) clinician network.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | RestorLife Med | YourHealthRx |
|---|---|---|
| WeighScore | 65.3/100 | 69.6/100 |
| Grade | C | C |
| Scorecard rank | #222 | #119 |
| Semaglutide | $199/mo (6-month plan, compounded) | $170/mo (compounded) |
| Tirzepatide | Not disclosed | $210/mo (compounded) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #222 · C
Strengths
- Verifiable LegitScript certification (seal ID 50400451) plus a named board-certified physician (Dr. Michael Wasef, MD) licensed in all 50 states
- Full GLP-1 lineup: compounded semaglutide and tirzepatide, plus gentler microdose entry options
- Generous support — unlimited care-team messaging, monthly check-ins, dosage adjustments, and 1 free blood test per quarter on the GLP-1 protocols
- Available in all 50 states with free priority shipping, discreet packaging, and roughly 48-hour delivery
- Transparent multi-month pricing with 50% off your first month; semaglutide protocols are compounded with B12
Where it loses points
- The advertised $299 is a struck-through anchor price, not a starting point: the real month-to-month rate is $299, a first month runs $149 at 50% off, and the $199 rate needs six months
- The page states its pricing is 'introductory and subject to change', so none of these figures is committed to
- The tirzepatide price is published the same way, against a struck-through anchor, and we could not establish which figure a buyer actually pays
- A separate semaglutide microdose is sold at $99/mo — a sub-therapeutic protocol, not a cheaper weight-loss dose
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #119 · C
Strengths
- Available in all 50 states and DC through a multi-state (IMLC) licensed clinician network
- Compounded semaglutide and tirzepatide in two formats - weekly injectable (with B12) or daily oral dissolving tablet
- Flat subscription price that doesn't change as your dose increases (no titration penalty)
- Science-forward, clinician-led, with built-in follow-up, lab testing, and a broad peptide and longevity catalog (BPC-157, TB-500, sermorelin, NAD+)
- Transparent, education-first positioning with published medical disclaimer, privacy, and terms
Where it loses points
- Eligibility and prescribing run through partner clinical workflows - YourHealthRx is the platform, not the prescriber or pharmacy
- Compounded medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- The compounding pharmacy partner is not named ('transparent sourcing' claimed but no pharmacy disclosed)
- Headline prices include a first-month intro rate; ongoing monthly cost is higher (semaglutide ~$170, tirzepatide ~$210)
- No LegitScript certification displayed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.